Opinion
Video
Author(s):
Katie S. Murray, DO, offers advice to urologists considering the adoption of newer treatment modalities for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), encouraging them to integrate these therapies into practice in light of the positive clinical trial data while emphasizing the potential for improved patient outcomes and the importance of staying informed about evolving treatment options.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.